Q1’22 revenues up 25% (ABGSCe 33%) Strong order intake, despite volatile environment Diversified ord...
Redeye retains its positive view of Infracom and raises its Base Case somewhat following Infracom’s ...
Goodbye Kansas Group inleder året starkt och ökar omsättningen och fortsätter att förbättra lönsamhe...
Redeye states that the quarterly financials were more or less in line with expectations.
Redeye states that the Q1 report was another step in the right direction in terms of sales and in li...
Sales 6% vs. ABG 5% vs. con Adj. EBITDA 8% vs. ABG 16% vs.
Redeye comments on Mestro’s Q1 2022 report, which was more or less in line with our expectations.
Nimbus går nu in det två säsongsmässigt starkaste kvartalen på året med rekordhög orderbok.
Redeye regards Devyser’s Q1’22 report as strong and was surprised by the high gross margin (83%), wh...
Safe at Sea är ett svenskt tillverkningsföretag av sök- och livräddningsbåtar för SAR-verksamhet (Se...
Q1 revenue was in line with our estimate, with a higher cost base than expected and a somewhat soft ...
Rovio arranged a CMD yesterday (11 May) in Stockholm, providing an update on its strategy and financ...
Redeye updates its estimates and valuation for Adverty, following the Q1’22 report.
We postpone timelines for some projects Major swap portfolio restructured – 40% secured to 2025 25x ...
Redeye finds that Gapwaves continues to progress according to plan (both operationally and versus ou...
Redeye states that the Q1 report was weaker than expected.
Duearity AB (”Duearity” eller ”Bolaget”) erbjuder unika lösningar för lindring och behandling av tin...
Redeye leaves its comments on Acarix following the announcement of its year-end report.
Hoylu ökade återkommande intäkter med 39 procent för årets första kvartal och genererade hela 14 nya...
Immunicum specialises in the research and development of novel immunotherapies that target hard-to-t...
